xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

661

Orlandi et al.

59. Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol . 2006;118(5):1133-1141. 60. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double blind, placebo-controlled, parallel-group phase 3 trials. The Lancet . 2019;394(10209):1638-1650. 61. Stevens WW, Peters AT, Tan BK, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract . 2019;7(8):2812 2820.e2813. 62. Soler ZM, Wittenberg E, Schlosser RJ, Mace JC, Smith TL. Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope . 2011;121(12):2672-2678. 63. Gliklich RE, Metson R. The health impact of chronic sinusi tis in patients seeking otolaryngologic care. Otolaryngol Head NeckSurg . 1995;113(1):104-109. 64. Gliklich RE, Metson R. Techniques for outcomes research in chronic sinusitis. Laryngoscope . 1995;105(4 Pt 1):387-390. 65. Remenschneider AK, D’Amico L, Gray ST, Holbrook EH, Gliklich RE, Metson R. The EQ-5D: a new tool for study ing clinical outcomes in chronic rhinosinusitis. Laryngoscope . 2015;125(1):7-15. 66. DeConde AS, Mace JC, Bodner T, et al. SNOT-22 qual ity of life domains differentially predict treatment modality selection in chronic rhinosinusitis. Int Forum Allergy Rhinol . 2014;4(12):972-979. 67. Hoehle LP, Phillips KM, Bergmark RW, Caradonna DS, Gray ST, Sedaghat AR. Symptoms of chronic rhinosinusitis differ entially impact general health-related quality of life. Rhinol ogy . 2016;54(4):316-322. 68. Ference EH, Stubbs V, Lidder AK, et al. Measurement and comparison of health utility assessments in chronic rhinosi nusitis. Int Forum Allergy Rhinol . 2015;5(10):929-936. 69. Chester AC, Sindwani R, Smith TL, Bhattacharyya N. Fatigue improvement following endoscopic sinus surgery: a system atic review and meta-analysis. Laryngoscope . 2008;118(4):730 739. 70. Alt JA, Smith TL, Mace JC, Soler ZM. Sleep quality and disease severity in patients with chronic rhinosinusitis. Laryngoscope . 2013;123(10):2364-2370. 71. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychome tric validity of the 22-item Sinonasal Outcome Test. ClinOto laryngol . 2009;34(5):447-454. 72. Benninger MS, Senior BA. The development of the rhinos inusitis disability index. Arch Otolaryngol Head Neck Surg . 1997;123(11):1175-1179. 73. Bengtsson C, Lindberg E, Jonsson L, et al. Chronic rhinos inusitis impairs sleep quality: results of the GA2LEN study. Sleep . 2017;40(1). 74. Soler ZM, Eckert MA, Storck K, Schlosser RJ. Cognitive func tion in chronic rhinosinusitis: a controlled clinical study. Int Forum Allergy Rhinol . 2015;5(11):1010-1017. 75. Rowan NR, Schlosser RJ, Storck KA, Ganjaei KG, Soler ZM. The impact of medical therapy on cognitive dysfunc tion in chronic rhinosinusitis. Int Forum Allergy Rhinol . 2019;9(7):738-745.

the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol . 2013;131(6):1479-1490. 42. Succar EF, Turner JH. Recent advances in understanding chronic rhinosinusitis endotypes. F1000Res . 2018;7. 43. Bachert C, Akdis CA. Phenotypes and emerging endotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract . 2016;4(4):621-628. 44. Husain Q, Sedaghat AR. Understanding and clinical rele vance of chronic rhinosinusitis endotypes. Clin Otolaryngol . 2019;44(6):887-897. 45. Cao P-P, Wang Z-C, Schleimer RP, Liu Z. Pathophysio logic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes. Ann Allergy Asthma Immunol . 2019;122(1):33-40. 46. Turner JH, Chandra RK, Li P, Bonnet K, Schlundt DG. Iden tification of clinically relevant chronic rhinosinusitis endo types using cluster analysis of mucus cytokines. J Allergy Clin Immunol . 2018;141(5):1895-1897.e1897. 47. Divekar R, Rank M, Squillace D, Kita H, Lal D. Unsuper vised network mapping of commercially available immunoas say yields three distinct chronic rhinosinusitis endotypes. Int Forum Allergy Rhinol . 2017;7(4):373-379. 48. Liao B, Liu JX, Li ZY, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy . 2018;73(7):1459-1469. 49. Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analy sis of biomarkers. J Allergy Clin Immunol . 2016;137(5):1449 1456.e1444. 50. Hoggard M, Waldvogel-Thurlow S, Zoing M, et al. Inflamma tory endotypes and microbial associations in chronic rhinosi nusitis. Front Immunol . 2018;9:2065. 51. Agache I, Akdis C, Jutel M, Virchow J. Untangling asthma phenotypes and endotypes. Allergy . 2012;67(7):835-846. 52. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Eng J Med . 2018;378(26):2486-2496. 53. Darveaux J, Busse WW. Biologics in asthma—the next step toward personalized treatment. J Allergy Clin Immunol Pract . 2015;3(2):152-160. 54. Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine pro files in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol . 2016;138(5):1344-1353. 55. Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol . 2018;141(5):1543-1551. 56. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcu taneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA . 2016;315(5):469-479. 57. Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: ran domized trial. J Allergy Clin Immunol . 2017;140(4):1024 1031.e1014. 58. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol . 2013;131(1):110 116 e111.